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AbstrACt
Objectives Shwachman-Diamond syndrome (SDS) is 
a rare autosomal recessive disorder. Its predominant 
manifestations include exocrine pancreatic insufficiency, 
bone marrow failure and skeletal abnormalities. Patients 
frequently present failure to thrive and susceptibility 
to short stature. Average birth weight is at the 25th 
percentile; by the first birthday, >50% of patients drop 
below the third percentile for height and weight. The study 
aims at estimating the growth charts for patients affected 
by SDS in order to give a reference tool helpful for medical 
care and growth surveillance through the first 8 years of 
patient’s life.
setting and participants This retrospective observational 
study includes 106 patients (64 M) with available 
information from birth to 8 years, selected among the 122 
patients included in the Italian National Registry of SDS 
and born between 1975 and 2016. Gender, birth date and 
auxological parameters at repeated assessment times 
were collected. The General Additive Model for Location 
Scale and Shape method was applied to build the growth 
charts. A set of different distributions was used, and the 
more appropriate were selected in accordance with the 
smallest Akaike information criterion.
results A total of 408 measurements was collected 
and analysed. The median number of observations per 
patient amounted to 3, range 1–11. In accordance with the 
methods described, specific SDS growth charts were built 
for weight, height and body mass index (BMI), separately 
for boys and girls. The 50th and 3rd percentiles of weight 
and height of the healthy population (WHO standard 
references) respectively correspond to the 97th and 50th 
percentiles of the SDS population (SDS specific growth 
charts), while the difference is less evident for the BMI.
Conclusions Specific SDS growth charts obtained 
through our analysis enable a more appropriate 
classification of patients based on auxological parameters, 
representing a useful reference tool for evaluating their 
growth during childhood.
IntrOduCtIOn 
Shwachman-Diamond syndrome (SDS) 
(OMIM 260400) is a rare autosomal recessive 
disorder first described in 1964,1 character-
ised by exocrine pancreas insufficiency, bone 
marrow failure and bone malformations.2–5 
Failure to thrive, susceptibility to infections 
and short stature are frequently observed in 
patients with SDS as well.1–4 6 
Pancreatic insufficiency early arises and 
is characterised by replacement of exocrine 
components with fatty tissue, but preserved 
islets of Langerhans and ductal architecture. 
Pancreatic function spontaneously improves 
over time in almost 50% of patients.2 4 7–9
Almost the totality of patients present 
persistent or intermittent neutropaenia.1 2 8–11 
Bone marrow biopsy reveals a hypoplastic 
‘marrow’ with varying degrees of fat infiltra-
tion.2 11 Up to 15%–20% of patients develop 
myelodysplastic syndrome, with high risk of 
acute myeloid leukaemia progression.12–15
In 2002, the gene (SBDS) involved in the 
syndrome was identified on chromosome 
7q11,16 although mutations in the DNAJC21 
gene have also been associated to an SDS 
phenotype, as well as, possibly, mutations of 
EFL1 and SRP54 genes.17–19 SBDS is widely 
expressed in mammalian tissue. In fact, other 
strengths and limitations of this study
 ► These growth charts represent the first set of 
normative curves for children with Shwachman-
Diamond syndrome (SDS) 0 to 8 years old.
 ► The 50th and 3rd percentiles of weight and height 
of the healthy population respectively correspond to 
the 97th and 50th percentiles of the SDS population.
 ► These charts should be principally used to compare 
the growth between SDS subjects of the same age 
and sex and also to recognise patients to investigate 
for growth hormone deficiency.
 ► The data used for the growth charts do not represent 
the natural development of the disease, but rather 
the growth development of SDS subjects receiving 
medical care.
 ► The present growth charts should be used with cau-
tion when studying patients with SDS of other ethnic 
backgrounds, as they show an accurate picture of 
the Italian SDS population.
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organs such as teeth and oral cavity, liver, heart, kidneys 
and skin may be involved.5 7 8
Currently, almost 10% of patients with SDS with clin-
ical features of SDS have lacked SBDS mutations.16 20 
However, the negative genetic test should not exclude the 
diagnosis. An accurate clinical evaluation is important in 
order to diagnose the presence of the syndrome.
Cognitive impairment has been noted in the majority 
of these patients, although with intragroup variability21–23; 
this has a serious impact on the patient, limiting inde-
pendence and quality of life.23 Neuroimaging studies24–26 
reported diffuse brain alterations in the brain structure 
and connectivity.
Several clinical studies reported failure to thrive associ-
ated with malnutrition. This is a common feature in the 
early stage of life, in particular prior to diagnosis. Growth 
failure is mainly due to inadequate nutrient intake in 
the presence or in the absence of feeding difficulties, 
pancreatic insufficiency and recurrent infections.1 2 4 8 27 
The average weight at birth is at the 25th percentile, 
and over half of the patients drop below the 3rd percen-
tile for both height and weight by the first birthday. 
After diagnosis and the start of an appropriate therapy, 
growth rate is restored to normal level in most of the 
children with SDS, even though it consistently remains 
below the third percentile for height and weight.2 4 9 27 
These alterations are not related to a pancreatic insuf-
ficiency or an inappropriate caloric intake, but seem 
to be directly linked to biallelic mutations of the SBDS 
gene, and the growth of these patients differs from that 
of healthy children.
To date, there are no specific SDS growth charts avail-
able unlike other disorders with marked growth retarda-
tion such as Down syndrome, Turner syndrome, Ellis-Van 
Creveld syndrome and achondroplasia.28–31 Indeed, 
disease-specific charts are a helpful tool in medical care, 
monitoring growth more accurately, and for research.
The aim of this retrospective multicentre observational 
study is to develop the growth chart for patients affected 
by SDS in order to provide a reference tool to monitor 
the growth of children with this disease throughout 
childhood.
Table 1 Number of patients and assessments
Age (years) F M Total
(1) Variable Number of patients
0–2 36 58 94
3–4 23 37 60
5–6 20 27 47
7–8 18 27 45
(2) Weight Number of assessments
0–2 91 141 232
3–4 27 44 71
5–6 29 41 70
7–8 17 18 35
Total 164 244 408
(3) Height Number of assessments
0–2 77 128 205
3–4 27 42 69
5–6 28 41 69
7–8 16 18 34
Total 148 229 377
(4) Body 
mass index Number of assessments
0–2 77 128 205
3–4 27 42 69
5–6 28 41 69
7–8 16 18 34
Total 148 229 377
(1) for each age class, the number of patients with available 
assessments is reported, separately for boys and girls; (2), (3) and 
(4) for each age class, the number of assessments for weight, 
height and BMI, respectively, is reported for boys and girls.
F, female; M, male.
Table 2 Main demographic and clinical characteristics of 
patients
Variables N (%)
Total 106
Gender
  Male 64 (60)
  Female 42 (40)
Age at diagnosis (months)
  Median (range) 13.8 months (0–35.6 years)
Gestational age (weeks)
  Median (range) 39 (29–42)
Pancreatic status
  Pancreatic sufficiency 15 (14)
  Pancreatic insufficiency 91 (86)
Heart problems
  No 99 (93)
  Yes 7 (7)
Bone lesions at diagnosis
  No 59 (56)
  Yes 47 (44)
Bone lesions during the first 8 years
  No 74 (70)
  Yes 32 (30)
GH*
  No 100 (94)
  Yes 6 (6)
*In five cases after the first 8 years of life, in one case at 7.5 years.
GH, growth hormone.
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MethOd
This study includes patients who are part of the Italian 
National Registry of SDS whose height, weight and main 
demographic characteristic were available in their first 8 
years of life. In the Registry, all 122 patients have an SDS 
diagnosis confirmed by genetic analysis. For each subject, 
the following characteristics were collected: gender, birth 
date, height, weight, assessment date and available clinic 
information. Measurements were recorded in accor-
dance with the standard criteria by age period. A total of 
645 observations on 122 patients was recorded, but data 
beyond 8 years of age was not included in the analysis 
owing to its being available for only 16 patients and at 
limited data points; thus, 408 observations on 106 patients 
with assessments in their first 8 years of life were analysed.
The primary endpoint was to estimate percentiles for 
height, weight and body mass index (BMI) for boys and girls.
The protocol was approved. All patients signed an 
informed consent to be included in the Registry.
Patient and public involvement
Patients were not involved in the design, recruitment and 
conduct of this study.
Data were initially prepared using the statistical software 
SAS and then analysed by the software R for growth curve 
estimation.32 A 3-month window was used for each of the 
three anthropomorphic measures; in case of multiple 
assessments, the average of the values available inside the 
window was considered. Growth curves for weight, height 
and BMI from birth to 8 years were constructed, each with 
3rd, 25th, 50th, 75th and 97th centiles for age. Data from 
male and female individuals were analysed separately.
Normative data for growth parameters were obtained 
from tables published by Cacciari et al.33 The Italian 
normative data were limited to 2–8 years, thus WHO data 
were used for ages 0–2.34 To model the growth charts, the 
General Additive Model for Location Scale and Shape 
package for the R statistical programme was used. This 
tool enables all the parameters of the distribution of the 
response variable to be modelled as linear/non-linear or 
smooth functions of the explanatory variables.35–37
The distribution of height, weight and BMI was 
modelled by the use of four parameters representing 
location, scale, skewness and kurtosis, using cubic penal-
ised smoothing lines. A set of different distributions was 
used, and the more appropriate were selected in accor-
dance with the criterion of the smallest Akaike informa-
tion criterion . Worm plots and q-q plots were used for the 
analysis of residuals.
With a sample size of 60 patients, the 50th, 25th/75th 
and 3rd/97th centiles could be estimated reaching an SE 
of about 0.8, 0.9 and 1.3, respectively.
results
A total of 106 patients (64 boys and 42 girls) were consid-
ered eligible for the analysis, with a total of 408 measure-
ments collected from 1975 to 2016, with a median number 
of three observations per patient, range 1–11 (table 1). All 
patients were Caucasian and of Italian origin, with a median 
age at diagnosis of 13.8 months, range 0 days–35.6 years. 
The median gestational age was 39 weeks, range 29–42, and 
the median weight at birth was 2.8 kg (0.85–4.2). Pancreatic 
insufficiency was observed in 91 patients (86%), all of them 
were on treatment with pancreatic enzymes. Six patients 
were treated with growth hormone (GH), five after their first 
8 years of life and one at age 7.5. Twelve patients out of 106 
underwent haematopoietic stem cell transplantation, 8 out 
of 12 under 8 years of age.
The main patient characteristics and mutations are 
reported in table 2 and table 3.
In accordance with the methods described, specific 
SDS growth charts were built for weight, height and 
BMI, separately for boys and girls. Each subject had the 
same number of observations for each growth parameter 
included in the database.
Figure 1 shows a growth chart for height (A and B), 
weight (C and D) and BMI (E and F) for boys and girls. 
Table 4 shows the 3rd, 25th, 50th, 75th and 97th centiles: 
the centiles are estimated every 3 months from birth to 2 
years, every 6 months from 2 to 6 years and once a year 
from 6 to 8 years.
In figure 2, the estimated SDS growth charts are shown 
together with Italian reference curves.
Compared with typically developing individuals (stan-
dard population), the values of the 97th and 50th centiles 
for height and weight of patients with SDS are located 
Table 3 Mutations of patients with Shwachman-Diamond 
syndrome 
Mutations N %
258+2T>C 183-184TA>CT 61 57.5
258+2T>C 183-184TA>CT+258+2T>C 16 15.1
258+2T>C 258+2T>C 9 8.5
258+2T>C c.258+533_459+403del 4 3.8
258+2T>C 101A>T 1 0.9
258+2T>C 107delT 1 0.9
258+2T>C 187G>T 1 0.9
258+2T>C 212C>T 1 0.9
258+2T>C 289-292del 1 0.9
258+2T>C 300delAC 1 0.9
258+2T>C 307-308delCA 1 0.9
258+2T>C 352A>G 1 0.9
258+2T>C 356G>A 1 0.9
258+2T>C 624+1G>C 1 0.9
258+2T>C 92-93GC>AG 1 0.9
258+2T>C G63C 1 0.9
258+2T>C IVS1-71del83bp 1 0.9
258+2T>C R218X 1 0.9
258+2T>C Y32C 1 0.9
523C>T 523C>T 1 0.9
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on the 50th and third centiles, respectively. At 8 years, 
the 50th centile for height in patients with SDS corre-
sponds to the 3rd centile and to the −2 SD value in the 
healthy population. The difference is less evident for 
the BMI centiles, meaning that the growth retardation is 
harmonic.
dIsCussIOn
SDS is a rare disease without a well-defined prevalence. 
Severe growth retardation (particularly in length/height) 
is one of its typical features, which can be alleged to be 
linked to the genetic cause of the disease.
At present, no growth charts have been validated for 
SDS; the charts we show here represent the first set of 
normative curves for children with SDS 0–8 years. As in 
healthy children, specific charts for SDS are important 
tools in monitoring treatment efficacy and for routine 
medical follow-up.
In this study, we used data from all children included 
in the Italian SDS registry with available assessments from 
Figure 1 Growth chart for height (A and B), weight (C and D) and body mass index (BMI) (E and F) for boys and girls (patients 
with Shwachman-Diamond syndrome). Curves for 3rd, 25th, 50th, 75th and 97th are reported in each graph.
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Table 4 Third, 25th, 50th, 75th and 97th are reported for patients with SDS from birth to 8 years
Age
Male Female
C3 C25 C50 C75 C97 C3 C25 C50 C75 C97
(1) Centiles for height
  0.00 41.8 46.2 48.6 51.1 55.5 38.1 44.3 46.8 48.8 51.8
  0.25 47.0 51.9 54.7 57.4 62.3 43.0 49.3 52.0 54.3 57.7
  0.50 51.7 57.2 60.2 63.1 68.4 47.8 54.2 57.0 59.5 63.4
  0.75 55.9 61.8 65.0 68.1 73.7 52.3 58.7 61.8 64.5 68.8
  1.00 59.6 65.8 69.2 72.5 78.4 56.5 62.9 66.1 69.0 73.8
  1.25 62.8 69.3 72.8 76.3 82.3 60.2 66.6 69.9 73.0 78.2
  1.50 65.5 72.3 75.9 79.5 85.7 63.3 69.8 73.2 76.5 81.9
  1.75 68.0 74.9 78.7 82.3 88.7 66.0 72.5 76.0 79.3 85.1
  2.00 70.1 77.2 81.0 84.8 91.2 68.3 74.8 78.4 81.8 87.8
  2.50 73.8 81.2 85.2 89.0 95.6 72.2 78.8 82.4 86.0 92.4
  3.00 77.1 84.8 88.8 92.7 99.4 75.8 82.6 86.3 90.0 96.6
  3.50 79.7 87.6 91.7 95.6 102.3 79.2 86.2 90.1 93.9 100.6
  4.00 82.1 90.1 94.3 98.2 104.9 82.3 89.7 93.7 97.5 104.3
  4.50 84.9 93.1 97.3 101.3 108.0 85.1 92.9 97.0 100.9 107.6
  5.00 87.9 96.3 100.5 104.6 111.2 87.2 95.7 99.9 103.8 110.2
  5.50 90.6 99.2 103.5 107.6 114.2 88.8 98.0 102.3 106.2 112.4
  6.00 93.4 102.1 106.5 110.6 117.3 90.5 100.4 104.8 108.7 114.7
  7.00 98.3 107.3 111.7 115.8 122.4 95.1 105.6 110.1 114.1 120.1
  8.00 103.0 112.2 116.6 120.7 127.3 100.7 110.6 115.1 119.1 125.5
(2) Centiles for weight
  0.00 1.5 2.6 2.9 3.3 4.0 1.6 2.3 2.7 3.1 3.7
  0.25 2.4 3.8 4.3 4.8 5.8 2.2 3.2 3.7 4.2 5.1
  0.50 3.2 4.9 5.5 6.1 7.3 2.9 4.1 4.7 5.4 6.4
  0.75 3.9 5.8 6.6 7.3 8.6 3.6 5.0 5.7 6.5 7.7
  1.00 4.6 6.6 7.5 8.3 9.7 4.3 5.8 6.7 7.5 9.0
  1.25 5.2 7.3 8.3 9.2 10.8 5.0 6.6 7.6 8.5 10.2
  1.50 5.8 7.9 9.0 10.0 11.7 5.6 7.3 8.3 9.4 11.2
  1.75 6.4 8.5 9.6 10.7 12.6 6.1 8.0 9.0 10.1 12.1
  2.00 6.9 9.0 10.2 11.4 13.5 6.6 8.6 9.7 10.8 13.0
  2.50 7.8 10.0 11.3 12.6 15.1 7.5 9.5 10.7 12.0 14.4
  3.00 8.6 10.9 12.3 13.7 16.5 8.3 10.4 11.6 13.0 15.6
  3.50 9.2 11.5 13.0 14.6 17.8 9.0 11.1 12.5 13.9 16.9
  4.00 9.8 12.1 13.7 15.4 19.0 9.7 11.9 13.3 14.9 18.1
  4.50 10.4 12.8 14.4 16.2 20.3 10.3 12.6 14.1 15.8 19.5
  5.00 11.0 13.4 15.1 17.1 21.8 10.9 13.3 14.9 16.7 20.8
  5.50 11.6 14.0 15.8 17.9 23.4 11.5 13.9 15.6 17.6 22.1
  6.00 12.3 14.7 16.5 18.8 25.2 12.1 14.6 16.4 18.5 23.5
  7.00 13.6 16.1 18.1 20.9 30.0 13.4 16.1 18.0 20.5 26.8
  8.00 15.5 18.1 20.3 23.6 37.2 15.2 18.0 20.2 23.0 31.2
(3) Centiles for body mass index (BMI)
  0.00 9.6 11.9 12.7 13.6 16.0 8.7 11.6 12.5 13.5 18.3
  0.25 10.3 12.5 13.4 14.3 16.9 9.8 12.3 13.3 14.2 18.4
  0.50 10.9 13.1 14.0 15.0 17.6 10.8 13.1 14.0 14.9 18.7
Continued
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birth to 8 years. All patients had SDS diagnosis confirmed 
by genetic mutations on both alleles, although up to 10% 
of subjects with SDS diagnosis described in the literature 
do not present mutations of the SBDS gene. In this way, 
we tried to reduce bias in our data set.
In spite of the rarity of the disease, we had the possibility 
to generate separate charts for boys and girls until the 
age of 8. When compared with normal (regular) growth 
charts, the SDS charts do not differ in form for this period 
of age. The 50th percentile of SDS charts for weight and 
height is positioned on the 3rd percentile of regular 
charts, both for boys and girls. The low percentile at birth 
for length and weight indicates that prenatal retardation 
occurs, then continuing in the postnatal period.
BMI curves are similar both for normal and SDS popu-
lation, indicating that the weight and height trend is 
harmonic also in SDS. These results as a whole suggest 
these growth curves are influenced by the genetic defect 
rather than malabsorption/malnutrition or inherited 
factors.
The SDS-specific growth charts can be used in 
managing problems related to growth, and may be useful 
to recognise patients who need investigations for GH defi-
ciency and for the possibility of specific treatment. These 
specific growth charts are also extremely useful to address 
nutritional counselling. The parents of patients with SDS 
regularly ask for the best diet to increase the growth of 
their children. Sometimes, an overfeeding behaviour has 
been reported with the aim of influencing height. This 
erroneous interpretation of growth problems in SDS may 
cause obesity and negative consequences on the skeletal 
apparatus.
Moreover, since there has been no growth chart avail-
able for patients with SDS until now, the growth charts 
developed in this study provide a significant impact in 
understanding physical trends in these subjects.
Given the small number of observations beyond 8 years, 
the growth charts were curtailed at age 8.
Several associated manifestations of the syndrome, such 
as heart, renal or skeletal alteration, could theoretically 
influence the growth of the patients. In our set, comor-
bidity risk factors able to influence growth retardation 
were not identified. In any case, given the rarity of the 
disease and the consequent small sample size, children 
with medical problems were not excluded, as already 
done in other similar works.38 39
It is also well known that SDS subjects may be recognised 
by the presence of typical clinical features, but variable 
penetrance and expressivity are common, which, together 
with the rarity of these patients, makes a correlation geno-
type-phenotype difficult.
A few limitations in our study are to be taken into 
account; one is that the data used for the growth charts 
do not represent the natural development of the disease, 
but rather the growth development of SDS subjects 
receiving medical care. We are aware that the data used 
in constructing growth charts should ideally come from 
prospective longitudinal studies on large groups; however, 
when considering rare syndromes, this approach cannot 
be used.
Age
Male Female
C3 C25 C50 C75 C97 C3 C25 C50 C75 C97
  0.75 11.3 13.6 14.5 15.5 18.3 11.6 13.7 14.6 15.6 19.0
  1.00 11.7 14.0 14.9 15.9 18.8 12.3 14.2 15.1 16.1 19.2
  1.25 12.0 14.3 15.2 16.2 19.1 12.9 14.6 15.5 16.4 19.4
  1.50 12.3 14.4 15.4 16.3 19.4 13.3 14.9 15.8 16.7 19.5
  1.75 12.4 14.6 15.5 16.4 19.5 13.6 15.1 15.9 16.8 19.5
  2.00 12.6 14.6 15.5 16.5 19.7 13.8 15.2 16.0 16.8 19.4
  2.50 12.8 14.7 15.6 16.6 19.9 13.8 15.1 15.8 16.6 19.0
  3.00 12.9 14.8 15.6 16.6 20.0 13.6 14.8 15.5 16.3 18.5
  3.50 12.9 14.7 15.6 16.5 20.1 13.5 14.6 15.2 16.0 18.3
  4.00 12.8 14.6 15.4 16.4 20.2 13.4 14.4 15.1 15.9 18.3
  4.50 12.7 14.4 15.3 16.3 20.3 13.4 14.4 15.1 15.9 18.5
  5.00 12.6 14.2 15.1 16.1 20.4 13.4 14.4 15.1 16.0 19.0
  5.50 12.5 14.0 14.9 16.0 20.5 13.3 14.3 15.0 16.0 19.4
  6.00 12.4 14.0 14.8 15.9 20.7 13.1 14.2 14.9 15.9 19.8
  7.00 12.4 14.0 14.9 16.1 21.5 13.0 14.0 14.8 15.9 20.5
  8.00 12.7 14.2 15.2 16.5 22.4 13.2 14.4 15.2 16.4 21.3
The estimates are reported every 3 months from birth to 2 years, every 6 months from 2 to 6 years and once a year from 6 to 8 years.
SDS, Shwachman-Diamond syndrome.
Table 4 Continued 
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In Italy, as well as in many Northern European coun-
tries, the secular trend has slowed down or even reached 
a plateau since the 1980s/1990s. Since only less than 3% 
of measurements included in this study were collected 
before 1980, no correction for the secular trend was 
considered.40 41
Furthermore, the present curves do not quite grasp 
the age of puberty, and definitive information on 
what affects the final height could not be obtained. 
In any case, the literature includes some patients with 
SDS older than 18 with percentiles remaining in the 
low average or below the third percentile for both 
weight and height,3 4 indicating that the growth spurt 
does not lead to a substantial change in the trend of 
growth.
The number of older patients at the moment is small; 
therefore, the charts may not be sufficiently reliable at 
the ages over 8 years. This is a typical limitation in pres-
ence of small numbers of patients, and is shared by other 
reference charts for rare diseases.
Figure 2 Estimated Shwachman-Diamond syndrome (SDS) growth charts compared with reference Italian curves. The values 
of 97th and 50th centiles for height and weight of patients with SDS are located on the 50th and 3rd centiles of the reference 
population. The difference is less evident for the body mass index (BMI) centiles.
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The present growth charts can be used to compare the 
growth of SDS individual (height, weight, BMI) and the 
general population, and also to compare the growth of an 
individual child with that of peers of the same age and sex 
with the syndrome.
SDS is a worldwide disease with patients diagnosed in 
every part of the world; the present growth charts should 
be used with caution when studying individuals with SDS 
of other ethnic backgrounds; as presented, the curves 
show an accurate picture of the Italian SDS population.
Future efforts will aim at collecting more data to 
improve knowledge on the syndrome and construct 
growth charts until 18 years of age. These tools would 
enable the gathering of more information on SDS, espe-
cially the influence of pubertal development on growth, 
as only sporadic data on this point are currently available.
Finally, when clinical trials aimed at assessing therapies 
for SDS basic defect are possible, similarly to other rare 
diseases,42 growth chart comparison in treated versus 
untreated SDS populations could be a relevant endpoint.
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